Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CHKA | P35790 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrrolidine SCHEMBL10413119 | 1.00 | FFAR3 (0.56) | FFAR3ALDH1A1CA2CHKASMN1; SMN2 | |
| Piperidine SCHEMBL6861563 | 1.00 | FFAR3 (0.56) | FFAR3ALDH1A1CA2CHKASMN1; SMN2 | |
| Pyrrolidine SCHEMBL28213560 | 1.00 | FFAR3 (0.56) | FFAR3ALDH1A1CA2CHKASMN1; SMN2 | |
| Piperidine SCHEMBL28047155 | 0.95 | FFAR3 (0.50) | FFAR3ALDH1A1CA2CHKASMN1; SMN2 | |
| Propionic Acid SCHEMBL9615008 | 0.92 | FFAR3 (0.59) | FFAR3ALDH1A1CA2CHKASMN1; SMN2 | |
| Propionic Acid SCHEMBL3790146 | 0.91 | — | — | |
| Piperazine SCHEMBL5818604 | 0.88 | FFAR3 (0.62) | FFAR3ALDH1A1CA2CHKAHDAC3 | |
| Propionic Acid SCHEMBL29104606 | 0.88 | — | — | |
| Piperazine SCHEMBL28214068 | 0.88 | FFAR3 (0.62) | FFAR3ALDH1A1CA2CHKAHDAC3 | |
| Piperidine SCHEMBL28044770 | 0.87 | FFAR3 (0.42) | FFAR3ALDH1A1SMN1; SMN2HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024219260-A1 | BEAUTY TREATMENT METHOD, METHOD FOR PROMOTING PERCUTANEOUS PENETRATION, AND BEAUTY TREATMENT KIT | 株式会社 資生堂 | 2024-10-24 | — | — | WO | claimed |
| US-20240293300-A1 | SKIN PENETRATION COSMETIC MATERIAL, AND SKIN PENETRATION COSMETIC MATERIAL PRODUCTION METHOD | SHISEIDO COMPANY, LTD. (JP) | 2024-09-05 | — | — | US | claimed |
| WO-2023002873-A1 | SKIN PENETRATION COSMETIC MATERIAL, AND SKIN PENETRATION COSMETIC MATERIAL PRODUCTION METHOD | 株式会社資生堂 | 2023-01-26 | — | — | WO | claimed |
| CN-110128136-B | Anti-static ceramic material and preparation method thereof | 亚细亚新材料科技股份公司 | 2022-04-19 | — | — | CN | claimed |
| CN-110128136-A | A kind of anti-electrostatic ceramic material and preparation method thereof | 谢红兵 | 2019-08-16 | — | — | CN | claimed |
| EP-1699753-B1 | IMPROVED PROCESS FOR THE PREPARATION OF ENTACAPONE | SUVEN LIFE SCIENCES LTD (IN) | 2014-11-26 | — | — | EP | claimed |
| CN-1906183-B | N-acylsulfonamide apoptosis promoters | ABBOTT LAB | 2012-06-20 | — | — | CN | claimed |
| US-20110054186-A1 | PROCESS FOR EPROSARTAN INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2011-03-03 | — | — | US | claimed |
| EP-2257540-A2 | IMPROVED PROCESS FOR EPROSARTAN INTERMEDIATE | Hetero Research Foundation (IN) | 2010-12-08 | — | — | EP | claimed |
| US-20100234632-A1 | PROCESS FOR THE PREPARATION OF ENTACAPONE | ALEMBIC LIMITED | 2010-09-16 | — | — | US | claimed |
| EP-1699753-A1 | IMPROVED PROCESS FOR THE PREPARATION OF ENTACAPONE | Suven Life Sciences Limited (IN) | 2006-09-13 | — | — | EP | claimed |
| CN-1249039-C | Inhibitors of 11 beta-hydroxysteroid dehydrogenase type I | BIOVITRUM AB (SE) | 2006-04-05 | — | — | CN | claimed |
| WO-2005063693-A1 | IMPROVED PROCESS FOR THE PREPARATION OF ENTACAPONE | SUVEN LIFE SCIENCES LTD (IN) | 2005-07-14 | — | — | WO | claimed |
| EP-0970073-B1 | PROCESS FOR PREPARING EPROSARTAN | SMITHKLINE BEECHAM CORP (US) | 2004-10-27 | — | — | EP | claimed |
| CN-1438997-A | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type I | BIOVITRUM AB (SE) | 2003-08-27 | — | — | CN | claimed |
| CN-1290165-A | Benzothiazole Protein tyrosine kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2001-04-04 | — | — | CN | claimed |
| EP-0970073-A4 | PROCESS FOR PREPARING EPROSARTAN | SMITHKLINE BEECHAM CORP (US) | 2001-01-24 | — | — | EP | claimed |
| US-6172237-B1 | Process for preparing eprosartan | SMITHKLINE BEECHAM CORPORATION | 2001-01-09 | — | — | US | claimed |
| EP-0970073-A1 | PROCESS FOR PREPARING EPROSARTAN | SMITHKLINE BEECHAM CORPORATION (US) | 2000-01-12 | — | — | EP | claimed |
| WO-1998035963-A1 | PROCESS FOR PREPARING EPROSARTAN | SMITHKLINE BEECHAM CORPORATION (US) | 1998-08-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054186-A1 | PROCESS FOR EPROSARTAN INTERMEDIATE | PTGER1, PTGER4, PDGFRA | FFAR3 28/4885ALDH1A1 761/4885CA2 3144/4885 |
| US-20240293300-A1 | SKIN PENETRATION COSMETIC MATERIAL, AND SKIN PENETRATION COSMETIC MATERIAL PRODUCTION METHOD | CUTA, SLC6A12, DSG1 | FFAR3 2703/4885ALDH1A1 1185/4885CA2 3587/4885 |
| US-20100234632-A1 | PROCESS FOR THE PREPARATION OF ENTACAPONE | DDC, GNE, GNPAT | FFAR3 3631/4885ALDH1A1 37/4885CA2 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.